For information on session dates and times, or to arrange interviews under embargo, please email sandy.van@miami.edu .
Agent orange exposure and the risk of incident myelodysplastic syndromes among Vietnam veterans from the VA million veteran program
Dr. Mikkael A. Sekeres is the last co-author.
One-year sustained MRD negativity and initial durability results from the phase 2 trial of abbreviated fixed-duration (default 4 vycles) linvoseltamab immunotherapy consolidation for newly diagnosed multiple myeloma (the IMMUNOPLANT Study)
Dr. Dickran Kazandjian is the presenting author and all of the co-authors are from Sylvester.
Teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: The REVIVE study
Dr. Ola Landgren is the presenting author and all of the co-authors are from Sylvester or the Miller School.
Updated results from LOTIS-7: A phase 1b study evaluating the safety and efficacy of loncastuximab tesirine in combination with glofitamab in patients with relapsed or refractory large B-cell lymphoma
Dr. Juan Pablo Alderuccio is the presenting author.
Fixed-duration loncastuximab tesirine induces a high rate of complete and durable responses in patients with relapsed/refractory marginal zone lymphoma - report of a multicenter phase II study
Dr. Izidore S.S. Lossos is the presenting author and most of the co-authors are from Sylvester or the Miller School.
Integrated spatial transcriptomics and whole genome sequencing of primary mediastinal B-cell lymphoma reveals genomically driven tumor/immune neighborhoods that correlate with clinical outcome
Dr. Izidore S.S. Lossos is a co-author.
Whole-genome sequencing of primary mediastinal B-cell lymphoma and classic Hodgkin lymphoma reveals key molecular differences tied to germinal center B-cell evolution and aging mutagenesis
Displacement of ABL1 exon 10 through exon skipping or duplication signifies a new genomic mechanism of clinical resistance to the BCR::ABL1 allosteric tyrosine kinase inhibitor asciminib
Ariel Leyte-Vidal, B.S., is the presenting author.
CAR-T cells generated from longitudinal sampling around frontline therapy for multiple myeloma reflect a spectrum of efficacy correlated to temporal differences in T lymphocyte fitness
Dr. Pinar Ataca Atilla is the presenting author and all of the co-authors are from Sylvester or the Miller School.
Baseline patient-reported fatigue and physical health independently predict survival in indolent B-cell lymphoma: Outcomes from the LEO cohort
Factor XI inhibition with abelacimab for treatment of cancer-associated thrombosis
Dr. Gerald A. Soff is a co-author.
Spatial communities shape tumor cell transcriptional states and patient outcomes in diffuse large B-cell lymphoma
Drs. Izidore S.S. Lossos and Jennifer Chapman are co-authors.
Spatial biology of advanced histologic grade in follicular lymphoma
Drs. Jennifer Chapman and Izidore S.S. Lossos are co-authors.
Durable remissions beyond 4 years after standard-of-care Brexucabtagene Autoleucel for relapsed/refractory mantle cell lymphoma: Long term follow-up from the US lymphoma CAR T consortium
Several Sylvester researchers are co-authors.
RALLY-MF: Efficacy of a Phase 2 study of selcodebart (DISC-0974), an anti-hemojuvelin antibody, to treat anemia in myelofibrosis
Dr. Sangeetha Venugopal is a co-author.
Harnessing distinct binding properties of HLA for ligand-based CAR-T cells against NKG2-expressing lymphomas
Daniel E. Chun-Chei Tsai, B.S., is the presenting author and all of the co-authors are from Sylvester or the Miller School.
Tumor-agnostic plasma cell-free DNA methylation profiling for measurable residual disease in patients with acute myeloid leukemia
Dr. Antonio M. Jimenez Jimenez is a co-author.
Targeting LSD1 potentiates menin inhibitor activity in KMT2A-rearranged and NPM1-mutated AML
Mina M. Tayari, Ph.D., is the presenting author and all of the co-authors are from Sylvester or the Miller School.
Macrocyclization creates a mechanistically distinct BTK inhibitor that overcomes kinase-impaired drug resistance
Erica N. Lamkin, M.Sc., is the presenting author and several co-authors are from Sylvester.
Prospective multicenter validation of whole genome-informed acute myeloid leukemia measurable residual disease testing: The MEASURE study
Stromal HSF1 activity builds a lymphoma-permissive niche and sustains a low-p53- activity tumor cell state in DLBCL
In JAK-inhibitor naive patients with myelofibrosis, mutant CALR-specific monoclonal antibody INCA033989 was well tolerated and achieved robust spleen, symptom, and anemia responses in Phase 1 studies
Dr. Terrence J. Bradley is a co-author.
Elranatamab (ELRA) monotherapy versus daratumumab plus pomalidomide and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM): Results from the phase 3 MagnetisMM-5 trial
Dr. Ola Landgren is the last co-author.
External validation of model-informed fludarabine exposure as a predictor of non-relapse mortality after PTCy-based allogeneic hematopoietic cell transplantation: Findings from the ACCESS trial
Cardiovascular outcomes in reduced intensity conditioning allogeneic HCT recipients receiving post-transplantation cyclophosphamide
Dr. Noa Holtzman is a co-author.
Redefining nodal T-follicular helper lymphoma, NOS through integrated molecular approaches: Implications for classification and prognosis
Dr. Catalina Amador is the presenting author and Abdessamad Youssfi Alaoui, Ph.D., and Dr. Jonathan H. Schatz are co-authors.
Bulky disease and/or elevated LDH identify a high-risk (HR) subgroup in international Prognostic Index (IPI) 1–2 newly diagnosed large B-cell lymphoma (LBCL): evidence from the LEO and REALYSA cohorts
HLA mismatched locus impact on outcomes in mismatched unrelated donor hematopoietic cell transplantation using post-transplant cyclophosphamide GVHD prophylaxis for acute leukemia or myelodysplastic syndrome: A CIBMTR retrospective analysis
Intermediate-dose post-transplantation cyclophosphamide for <7/8 HLA-mismatched unrelated donor peripheral blood stem cell transplantation: Safety run-in results from OPTIMIZE
Dr. Antonio M. Jimenez Jimenez is the presenting author.
Personalized DNA-based multiplex DDPCR for MRD detection in patients with KMT2A-altered AML
Phase I trial of methotrexate, rituximab, lenalidomide, and nivolumab as induction for primary central nervous system lymphoma: Dose-finding, response, and tolerability (Alliance A051901)
Dr. Alvaro Alencar is the presenting author and Dr. Macarena De La Fuente is a co-author.
A real-world cohort of immunomodulatory drug (IMiD) addition at the time of bispecific monotherapy response plateau or biochemical progression
Andrew Kowalski, Pharm.D., is the presenting author and all of the co-authors are from Sylvester.
Efficacy of anti-bias resident curriculum to improve sickle cell care quality
Rajit P. Hegde is a co-author.
Burnout and moral distress in the sickle cell disease physician workforce: A nationwide survey
Dr. Abul Andres Ariza-Manzano is a co-author.
Initial report of the Phase 2 pivotal data in patients with relapsed or refractory KMT2Ar acute leukemia from the phase 1/2 trial of the investigational menin inhibitor enzomenib (DSP-5336)
Dr. Justin M. Watts is a co-author.
Pre-transplant flow cytometry in AML patients undergoing allogeneic HCT after hypomethylating agent and venetoclax therapy
Patient-reported vulnerability using the vulnerable elders survey-13 (VES-13) complements ECOG performance status (ECOG PS) in predicting early death and long-term overall survival (OS) for adults with non-Hodgkin lymphoma (NHL)
Randomized controlled trial of a digital health application (Horizons App) for patients living with chronic graft versus host disease (cGVHD)
Several Sylvester or Miller School researchers are co-authors.
Interim analysis of a phase I/II, open label study to evaluate safety, tolerability, and efficacy of elranatamab in patients with relapsed AL amyloidosis
Dr. James E. Hoffman is a co-author.
Ruxolitinib plus duvelisib shows promising activity in T-follicular helper cell lymphoma
Dr. Jonathan H. Schatz is a co-author.
Multicenter cohort analysis of outcomes in limited stage large B-cell lymphoma based on therapeutic approach and disease characteristics
Artificial intelligence analysis of routine peripheral blood smears enables automated diagnostic triage for myelodysplastic syndromes
Dr. Mikkael A. Sekeres is a co-author.
Mutant CALR-specific monoclonal antibody INCA033989 produced molecular responses and restored normal hematopoiesis in patients with essential thrombocythemia in Phase 1 studies
Reduced-dose post-transplantation cyclophosphamide achieves high infection-free and overall survival in mismatched unrelated donor transplantation using reduced intensity/non-myeloablative conditioning: Initial results from OPTIMIZE
Intravenous fluid hydration for vaso-occlusive painful episodes in hospitalized children with sickle cell disease: Does tonicity matter?
Thrisha Kalpatthi, B.S., is the presenting author and Dr. Meghan McCormick is the last co-author.